Literature DB >> 17975498

The impact of genetic markers on the diagnosis of lung cancer: a current perspective.

Joanna Chorostowska-Wynimko1, Adam Szpechcinski.   

Abstract

Lung cancer is the leading worldwide source of cancer-related death. It is acknowledged that prognosis and treatment outcomes in lung cancer might be improved by increasing the effectiveness of early-stage diagnosis. Several recently published studies have produced intriguing results regarding the detection of biomarkers in tumor samples, but also in easily accessible specimens such as sputum, plasma, and exhaled breath condensate. This review presents advances in genetic diagnostics of lung cancer, with particular reference to the clinical usefulness of individual biomarkers, specimens, and methods. The adequacy of their sensitivity and specificity for cancer screening and early detection is discussed in detail.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17975498     DOI： 10.1097/JTO.0b013e318158eed4

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


  10 in total

Review 1.  Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer.

Authors:  M Cabanero; M S Tsao
Journal:  Curr Oncol       Date:  2018-06-13       Impact factor: 3.677

Review 2.  miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives.

Authors:  Mateusz Florczuk; Adam Szpechcinski; Joanna Chorostowska-Wynimko
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.493

3.  Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers.

Authors:  Kristy L Richards; Baili Zhang; Menghong Sun; Wenli Dong; Jennifer Churchill; Linda L Bachinski; Charmaine D Wilson; Keith A Baggerly; Guosheng Yin; D Neil Hayes; Ignacio I Wistuba; Ralf Krahe
Journal:  Cancer       Date:  2010-10-13       Impact factor: 6.860

Review 4.  Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Anthony J Alberg; Malcolm V Brock; Jean G Ford; Jonathan M Samet; Simon D Spivack
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

5.  BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization.

Authors:  Karen H Ventii; Narra S Devi; Kenneth L Friedrich; Tatiana A Chernova; Mourad Tighiouart; Erwin G Van Meir; Keith D Wilkinson
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

6.  Real-time PCR quantification of plasma DNA in non-small cell lung cancer patients and healthy controls.

Authors:  A Szpechcinski; M Dancewicz; P Kopinski; J Kowalewski; J Chorostowska-Wynimko
Journal:  Eur J Med Res       Date:  2009-12-07       Impact factor: 2.175

7.  SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates.

Authors:  Bernd Schmidt; Volker Liebenberg; Dimo Dietrich; Thomas Schlegel; Christoph Kneip; Anke Seegebarth; Nadja Flemming; Stefanie Seemann; Jürgen Distler; Jörn Lewin; Reimo Tetzner; Sabine Weickmann; Ulrike Wille; Triantafillos Liloglou; Olaide Raji; Martin Walshaw; Michael Fleischhacker; Christian Witt; John K Field
Journal:  BMC Cancer       Date:  2010-11-03       Impact factor: 4.430

8.  Correlation of SHOX2 gene amplification and DNA methylation in lung cancer tumors.

Authors:  Katja U Schneider; Dimo Dietrich; Michael Fleischhacker; Gunda Leschber; Johannes Merk; Frank Schäper; Henk R Stapert; Erik R Vossenaar; Sabine Weickmann; Volker Liebenberg; Christoph Kneip; Anke Seegebarth; Fikret Erdogan; Gudrun Rappold; Bernd Schmidt
Journal:  BMC Cancer       Date:  2011-03-22       Impact factor: 4.430

9.  Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease.

Authors:  A Szpechcinski; J Chorostowska-Wynimko; R Struniawski; W Kupis; P Rudzinski; R Langfort; E Puscinska; P Bielen; P Sliwinski; T Orlowski
Journal:  Br J Cancer       Date:  2015-06-30       Impact factor: 7.640

10.  Clinical significance of cell-free DNA as a prognostic biomarker in patients with diffuse large B-cell lymphoma.

Authors:  Mahsa Eskandari; Saba Manoochehrabadi; Hossein Pashaiefar; Mohammad Ali Zaimy; Mohammad Ahmadvand
Journal:  Blood Res       Date:  2019-06-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.